Newswire (Published: Tuesday, February 7, 2017, Received: Thursday, February 2, 2017, 5:27:13 PM CST)

Word Count: 457

Researchers at Shengjing Hospital Release New Data on Prostate Cancer (Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Liaoning, People's Republic of China, by NewsRx correspondents, research stated, "Prostate cancer (PCa) is one of the most common malignant tumors and a major cause of cancer-related death for men worldwide. The aim of our study was to identify potential non-invasive serum and expressed prostatic secretion (EPS)-urine biomarkers for accurate diagnosis of PCa."

Our news editors obtained a quote from the research from Shengjing Hospital, "Here, we performed a combined isobaric tags for relative and absolute quantification (iTRAQ) proteomic analysis to compare protein profiles using pooled serum and EPS-urine samples from 4 groups of patients: benign prostate hyperplasia (BPH), high grade prostatic intraepithelial neoplasia (HGPIN), localized PCa and metastatic PCa. The differentially expressed proteins were rigorously selected and further validated in a large and independent cohort using classical ELISA and Western blot assays. Finally, we established a multiplex biomarker panel consisting of 3 proteins (serum PF4V1, PSA, and urinary CRISP3) with an excellent diagnostic capacity to differentiate PCa from BPH [area under the receiver operating characteristic curve (AUC) of 0.941], which showed an evidently greater discriminatory ability than PSA alone (AUC, 0.757) (p <0.001). Importantly, even when PSA level was in the gray zone (4-10 ng/mL), a combination of PF4V1 and CRISP3 could achieve a relatively high diagnostic efficacy (AUC, 0.895). Furthermore, their combination also had the potential to distinguish PCa from HGPIN (AUC, 0.934)."

According to the news editors, the research concluded: "Our results demonstrated that the combined application of serum and EPS-urine biomarkers can improve the diagnosis of PCa and provide a new prospect for non-invasive PCa detection."

For more information on this research see: Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers. Discovery Medicine, 2016;22(122):281-295 (see also Oncology - Prostate Cancer).

The news editors report that additional information may be obtained by contacting M. Zhang, Urology Department, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China. Additional authors for this research include L. Chen, Z. Yuan, Z. Yang, Y. Li, L. Shan, B. Yin, X. Fei, J. Miao and Y. Song.

Keywords for this news article include: Asia, Liaoning, Oncology, Proteomics, Technology, Prostate Cancer, Prostatic Neoplasms, Diagnostics and Screening, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

China Medical University

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Eastern Asia
People's Republic of China
Asia
Liaoning
Shenyang

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Genetics
                  Proteomics
      Medical Specialties and Practices
            Urology